They Develop a Blood Biomarker Capable of Predicting Dementia in Alzheimer’s

El Progreso de Lugo

Factuality

Ownership

The innovative 'Map-AD' test, developed by the Bellvitge Biomedical Research Institute (Idibell) of L'Hospitalet de Llobregat, is able to anticipate the progression of mild cognitive impairment towards Alzheimer's dementia

www.larazon.es

Factuality

Ownership

The spin off of IDIBELL, ADmit Therapeutics, and researchers from Bellvitge Hospital have developed a biomarker in blood that allows to predict dementia in Alzheimer’s, being the first of these characteristics that is created in Spain, since the previous ones were developed outside and validated here, and also everything suggests that it is the one that allows to diagnose the disease earlier. The particularity of this predictive tool is that, un…

VilaWeb.cat

Factuality

Ownership

ADmit Therapeutics, a company spun off from IDIBELL, with Bellvitge Hospital as the clinical coordinating center, has discovered and developed a blood biomarker that, for the first time, allows for the anticipation of the progression of mild cognitive impairment towards Alzheimer's dementia. Unlike other biomarkers recently developed by international teams, which serve to confirm the presence of brain pathology, the new MAP-AD test is prognostic…

ElNacional.cat

Factuality

Ownership

The new test created by a company derived from Bellvitge provides key information on the future evolution of the patient

Salud a Diario

Factuality

Ownership

Unlike other biomarkers in blood recently developed by international teams, which serve to confirm the presence of brain pathology, the new MAP-AD® test is a prognosis and provides decisive clinical information on the future evolution of each patient towards the Alzheimer. The results of the research, published in iScience magazine (Cell Press), have allowed the development of the MAP-AD® test, created by the company ADmit Therapeutics, spin-off…